Participate in Research

Human Subjects Protection Training
Participate in Research 
Researchers
Research Studies 

We are currently seeking participants for the following studies:

HPV Prevalence Study

The HPV Prevalence Study is currently recruiting biologically born males (regardless of gender expression or identity) aged 18-26 to help us determine the prevalence of human papillomavirus (HPV) and assess knowledge, attitudes, and practices regarding HPV vaccination. Participants will be compensated for their time.

If interested, please contact Michael Maloney at 773.388.8898 or MmaloneY@howardbrown.org.

Bitch to Quit (BTQ) Smoking Cessation Research Study 

The Bitch to Quit program was specifically developed to address the needs of LGBT smokers. The program is based on knowledge and activities that have been proven to be effective with heterosexual smokers. In addition, we have created new materials that are LGBT specific. The Bitch to Quit program includes group counseling sessions with trained facilitators, nicotine replacement, and peer support. Our first goal of this project is to help YOU reach your stop smoking goals. Our second goal is to test how well the program works for LGBT smokers in general.

BTQ exists because smoking rates in the LGBT communities are sky high. Results of a recent study show that approximately 35% of all LGBT people smoke – this compares to about 20% of all heterosexual people. Despite higher smoking rates, there are very few stop smoking programs that have been specifically developed for LGBT smokers. Many experts agree that we need to develop and test programs that can assist LGBT smokers who are ready to quit. Bitch to Quit (BTQ) is proud to be one of the first studies in the nation focusing on smoking in the LGBTQ community! The study is currently seeking adult lesbian, gay, bisexual, transgender, and queer (LGBTQ) smokers who are interested in quitting smoking. The study includes 6 group-counseling sessions, 8 weeks of nicotine patches, and compensation for time and travel!

For more information, please call 773-388-8868 or e-mail BTQ@howardbrown.org

Currently Recruiting Clinical Trials

Pfizer A4001067
Pfizer A4001067 is an International, Multicenter, Prospective Observational Study of the Safety of Maraviroc used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients. Eligible participants will be compensated for time. The Principal Investigator (PI) for this study is Dr. Catherine Creticos, MD.

For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org  or 773-572-5116.

GlaxoSmithKline ING114916
ING114916 is a Dolutegravir Open Label Protocol for HIV infected Adult Patients with Integrase Resistance. Participants are eligible to receive Dolutegravir as part of this Expanded Access Program. The Principal Investigator (PI) for this study is Dr. Magda Houlberg, MD.

For more information, please contact Christina Abaya at ChristinaA@howardbrown.org or 773-388-8792.

Merck & Co., Inc. Quality of Life
Quality of Life of HIV-infected Patients Switching to Raltegravir Versus other Antiretroviral Regimens. Eligible participants will be compensated for time. The Principal Investigators (PIs) for this study are Kristin Keglovitz Baker, PA and John Styker, NP.

For more information, please contact Kenyetta Drummond at KenyettaD@howardbrown.org or 773-572-5116.

Gilead GS-US-292-0111
GS-US-292-0111 is A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment- Naïve Adults. Eligible participants receive study medication and associated labs at no charge and are compensated for time. The Principal Investigator (PI) for this study is Dr. Catherine Creticos, MD.

For more information, please contact Christina Abaya at ChristinaA@howardbrown.org or 773-388-8792.